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L ung transplantation (LT) is the last resort for end-stage lung disease [1].  Survival after LT has been 
improving decade by decade [1],  which has led to an 
increase in long-term survivors after LT [2].  However,  
long-term survivors after LT are generally susceptible to 
chronic kidney disease (CKD),  which is a common 
complication after non-renal organ transplantation 
[3 , 4] and is associated with a 4- to 5-fold increased risk 
of mortality after LT [5].  As a renal replacement ther-
apy for CKD,  late living-donor kidney transplantation 
(LDKT) after LT has been shown to be associated with 
excellent long-term survival as well as acceptable kidney 
and lung allograft function [6].  Accordingly,  improved 
survival after LT results in an increased number of 
long-term survivors after LT who require KT for CKD.  
Although the number of LT recipients in Japan reached 
763 at the end of 2019,  to the best of our knowledge,  
KT after LT has never been reported in Japan.  We 
describe the long-term follow-up findings of a patient 
who underwent LDKT for CKD 18 years after receiving 
bilateral cadaveric LT.
Case Report
The details of the patient’s clinical course before and 
after his initial cadaveric LT are described in a previous 
report [7].  Briefly,  an 18-year-old male with idiopathic 
pulmonary arterial hypertension underwent bilateral 
cadaveric LT and closure of a patent foramen ovale in 
the United States before the establishment of the organ 
transplant law in Japan.  His postoperative immuno-
suppression regimen consisted of cyclosporine,  azathi-
oprine and prednisolone.  However,  cyclosporine and 
azathioprine were switched to tacrolimus and mycophe-
nolic acid due to a temporary decline in forced expira-
tory volume in 1 sec (FEV1) that raised suspicions of 
chronic lung allograft dysfunction (CLAD) 14 years 
after LT.  The patient’s renal function gradually wors-
ened during the chronic phase after LT.  Despite a 
switch in his immunosuppression protocol from twice-
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daily tacrolimus to once-daily prolonged-release tacro-
limus to maintain serum trough levels around 5 ng/mL,  
he ultimately required renal replacement therapy.  
Hemodialysis was initiated at age 35 (Fig. 1),  at which 
time his lung function was preserved with no evidence 
of CLAD after LT (Fig. 2).
At the age of 37,  18 years after his initial LT,  the 
patient underwent LDKT using the right kidney of his 
mother.  His postoperative immunosuppression regi-
men for KT consisted of once-daily prolonged-release 
tacrolimus,  mycophenolic acid and prednisolone.  The 
target trough level of tacrolimus was around 10 ng/mL.  
The patient’s postoperative course was uneventful,  
however,  he developed a non-tuberculous mycobacte-
rial (NTM) infection in the transplanted lungs 
8 months after KT (Fig. 3).  The target trough level of 
tacrolimus was then decreased to around 5 ng/mL.  The 
patient received triple-antibiotic therapy consisting of 
imipenem/cilastatin,  amikacin and clarithromycin to 
treat the NTM infection,  which resolved 12 months 
after KT.  After the resolution of the NTM infection,  the 
patient’s forced vital capacity (FVC) and FEV1 decreased 
from 4,635 to 3,880 mL and from 3,680 to 2,520 mL,  
respectively.  At 21 months after KT (20 years after the 
initial LT; Fig. 2),  he was diagnosed with CLAD,  
which was treated with azithromycin.  Because the 
patient’s impaired lung function remained stable and 
CLAD progression was prevented,  azithromycin was 
discontinued 3 years after the diagnosis of CLAD to 
protect his renal function.  Despite CLAD after LT,  he 
returned to his normal social life and,  at the time of 
writing,  has survived without the development of CKD 
for 8 years after KT,  which corresponds to 26 years 
after the initial LT.
Discussion
Lifelong immunosuppression,  which is inevitable 
after LT,  is associated with the development of late 
complications such as malignant tumors [8],  infectious 
disease [1],  and CKD [1].  CKD is caused mainly by 
calcineurin inhibitors of immunosuppresive agents,  
which lead to the development of renal ischemic injury 
and the activation of proinflammatory and profibrotic 
mediators,  resulting in renal interstitial inflammation 
and fibrosis [9].  To the best of our knowledge,  this is 
the first report of a successful case of LDKT for CKD 
after bilateral cadaveric LT in Japan.  In our case,  the 
patient developed CLAD 20 years after LT,  triggered by 
an NTM infection after KT.  CLAD is defined as an irre-




























Fig.  1　 Postoperative changes in serum creatinine levels after 
lung transplantation.  After the patient underwent living-donor kidney 

























Fig.  2　 Postoperative changes in forced expiratory volume in one 
second (FEV1) and forced vital capacity (FVC) values after lung 
transplantation.  The patient developed chronic lung allograft dys-
function (CLAD) after a non-tuberculous mycobacterial (NTM) 
infection.  FEV1 and FVC were maintained after treatment with azi-
thromycin for CLAD.
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Fig.  3　 Chest computed tomography showing non-tuberculous 
mycobacterial (NTM) infection in the bilateral lungs (A) and the 
resolution of NTM at the diagnosis of chronic lung allograft dys-
function (CLAD) (B).  The nodular shadows in the bilateral lungs 
(A) improved after treatment for NTM at the time of the diagnosis of 
CLAD (B).
versible decline of FEV1 to < 80% of the baseline value,  
which is calculated as the average of the two best FEV1 
values obtained at least 3 weeks apart,  according to the 
classification system proposed by the International 
Society of Heart and Lung Transplantation [10].  
Fortunately,  the progression of CLAD was prevented in 
our case by treatment with azithromycin for more than 
8 weeks,  which is one of the recommended treatment 
options for CLAD [10].  We speculate that the patient’s 
altered immunosuppression status after KT may have 
caused the NTM infection in the lungs [11]; therefore,  
care must be taken in the management of immunosup-
pression therapy in KT after LT.  In addition,  as part of 
the management of NTM after LT,  physicians must pay 
close attention to interactions between calcineurin 
inhibitors for immunosuppression and antibiotics for 
NTM,  especially rifampicin [12].
Because the average wait time for cadaveric KT is 
more than 14 years due to a severe shortage of donors in 
Japan,  LDKT,  as performed for various end-stage kid-
ney diseases,  is a realistic option for CKD after LT.  
LDKT after LT has been shown to provide excellent 
long-term outcomes [6].  In Japan,  living-donor lobar 
LT from two healthy donors,  including blood relatives 
within the third degree and a spouse,  was mainly per-
formed until the organ transplant law was modified in 
2010 [13].  Even in living kidney donation,  an increased 
risk of postoperative pulmonary complications is asso-
ciated with an FEV1 of < 70%,  an FVC of < 70% of the 
predicted value,  or a FEV1/FVC ratio of < 65% [14].  
Given the donor’s decreased lung function after living 
lobar lung donation,  living kidney donation from the 
same donor might be difficult.  In our case,  since the 
patient initially underwent cadaveric LT rather than 
living-donor lobar LT,  a living donor was fortunately 
available for KT.  Further accumulation of cases of KT 
after LT is required for a detailed evaluation in Japan.
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